New pill aims to cut COPD attacks in half
NCT ID NCT07349524
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a new tablet called RSS0343 can safely reduce the number of moderate or severe COPD flare-ups. About 300 adults with COPD will receive either the drug or a placebo for 48 weeks. The main goal is to see if the drug lowers the yearly rate of serious breathing attacks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RSS0343 tablets
What this could lead to
If successful, this could provide a new treatment option to reduce the number of serious COPD flare-ups.
What could go wrong
This is an early phase II trial with only 300 participants, so results may not apply to everyone. The drug may not work better than placebo or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
First Affiliated Hospital of Guangzhou Medical University
RECRUITINGGuangzhou, Guangdong, 510140, China
Contact